Skip to main content

Table 1 Comparison of patient’s characteristics between groups of treatment

From: GnRH agonists to sustain the luteal phase in antagonist IVF cycles: a randomized prospective trial

 AHAHT1AHT2 
Mean age group < 3533,4 ± 1,733,7 ± 1,332,8 ± 1,7NS
Mean age group ≥3538,6 ± 2,338,1 ± 2,438,9 ± 2,1NS
% nulliparous73,4%71,8%74,1%NS
% male factor24,9%27,1%22,6%NS
% tubal factor12,3%12,7%14,0%NS
% mixed factor or no factor62,8%60,2%63,4%NS
Mean BMI group < 3522,3 ± 2,823,1 ± 2,622,1 ± 3,3NS
Mean BMI group > 3524,3 ± 3,724,2 ± 3,424,5 ± 3,5NS
  1. AH Antagonist cycles with only Progesterone in luteal phase
  2. AHT1 Antagonist cycles with addition of luteal triptorelin as multiple injections
  3. AHT2 Antagonist cycles with addition of luteal triptorelin as single bolus